Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Lymphoma

ClinicalTrials.gov lists 8,343 trials for Lymphoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 411.

MeSH D008223 Neoplasms Neoplasm C04 C15 C20 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 2,032 Phase 1/2 Phase 1/2 969 Phase 2 Phase 2 2,632 Phase 2/3 Phase 2/3 76 Phase 3 Phase 3 617 Phase 4 Phase 4 145 Not applicable Not applicable 801 Observational Observational 1,037 Phase 1 Phase 1 2,032 Phase 1/2 Phase 1/2 969 Phase 2 Phase 2 2,632 Phase 2/3 Phase 2/3 76 Phase 3 Phase 3 617 Phase 4 Phase 4 145 Not applicable Not applicable 801 Observational Observational 1,037

Trials per phase (log scale)

2 more sections with rows

3,010 of the 8,343 trials are tagged with Lymphoma itself; the rest are tagged with a narrower condition beneath it.

Get the Lymphoma report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Lymphoma trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 18 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 439

1990: 8 trials (Not applicable 1, Phase 2 5, Phase 1 2) 1991: 6 trials (Not applicable 1, Phase 2 3, Phase 1 2) 1992: 14 trials (Observational 2, Phase 3 2, Phase 2 7, Phase 1/2 1, Phase 1 2) 1993: 16 trials (Observational 3, Not applicable 1, Phase 3 3, Phase 2 7, Phase 1 2) 1994: 21 trials (Observational 3, Phase 3 6, Phase 2 9, Phase 1 3) 1995: 35 trials (Observational 2, Phase 4 2, Phase 3 8, Phase 2/3 1, Phase 2 14, Phase 1/2 3, Phase 1 5) 1996: 42 trials (Observational 6, Not applicable 2, Phase 3 6, Phase 2 18, Phase 1/2 1, Phase 1 9) 1997: 65 trials (Observational 6, Not applicable 3, Phase 3 13, Phase 2/3 1, Phase 2 21, Phase 1/2 4, Phase 1 17) 1998: 90 trials (Observational 3, Not applicable 5, Phase 4 1, Phase 3 14, Phase 2/3 1, Phase 2 43, Phase 1/2 6, Phase 1 17) 1999: 104 trials (Observational 5, Not applicable 6, Phase 3 15, Phase 2/3 1, Phase 2 39, Phase 1/2 8, Phase 1 30) 2000: 132 trials (Observational 9, Not applicable 10, Phase 4 2, Phase 3 19, Phase 2/3 1, Phase 2 62, Phase 1/2 10, Phase 1 19) 2001: 112 trials (Observational 8, Not applicable 11, Phase 4 1, Phase 3 16, Phase 2 44, Phase 1/2 8, Phase 1 24) 2002: 130 trials (Observational 7, Not applicable 11, Phase 4 3, Phase 3 11, Phase 2/3 2, Phase 2 57, Phase 1/2 17, Phase 1 22) 2003: 167 trials (Observational 7, Not applicable 16, Phase 4 3, Phase 3 28, Phase 2/3 3, Phase 2 64, Phase 1/2 21, Phase 1 25) 2004: 213 trials (Observational 17, Not applicable 16, Phase 4 5, Phase 3 19, Phase 2/3 2, Phase 2 99, Phase 1/2 17, Phase 1 38) 2005: 216 trials (Observational 22, Not applicable 15, Phase 4 3, Phase 3 18, Phase 2/3 1, Phase 2 101, Phase 1/2 19, Phase 1 37) 2006: 233 trials (Observational 18, Not applicable 12, Phase 4 7, Phase 3 21, Phase 2/3 1, Phase 2 103, Phase 1/2 23, Phase 1 48) 2007: 268 trials (Other 1, Observational 24, Not applicable 18, Phase 4 2, Phase 3 19, Phase 2/3 1, Phase 2 98, Phase 1/2 23, Phase 1 82) 2008: 247 trials (Observational 39, Not applicable 15, Phase 4 2, Phase 3 17, Phase 2/3 2, Phase 2 88, Phase 1/2 28, Phase 1 56) 2009: 237 trials (Other 1, Observational 34, Not applicable 16, Phase 4 6, Phase 3 15, Phase 2/3 1, Phase 2 93, Phase 1/2 18, Phase 1 53) 2010: 254 trials (Observational 29, Not applicable 19, Phase 4 6, Phase 3 21, Phase 2/3 4, Phase 2 82, Phase 1/2 32, Phase 1 61) 2011: 265 trials (Observational 37, Not applicable 12, Phase 4 6, Phase 3 22, Phase 2 97, Phase 1/2 24, Phase 1 67) 2012: 250 trials (Observational 33, Not applicable 20, Phase 4 7, Phase 3 25, Phase 2 74, Phase 1/2 29, Phase 1 62) 2013: 252 trials (Observational 29, Not applicable 15, Phase 4 7, Phase 3 26, Phase 2/3 2, Phase 2 62, Phase 1/2 28, Phase 1 83) 2014: 247 trials (Observational 29, Not applicable 26, Phase 4 6, Phase 3 17, Phase 2 58, Phase 1/2 47, Phase 1 64) 2015: 289 trials (Observational 32, Not applicable 23, Phase 4 7, Phase 3 24, Phase 2/3 2, Phase 2 100, Phase 1/2 40, Phase 1 61) 2016: 359 trials (Observational 45, Not applicable 22, Phase 4 12, Phase 3 16, Phase 2/3 8, Phase 2 108, Phase 1/2 56, Phase 1 92) 2017: 379 trials (Observational 42, Not applicable 41, Phase 4 4, Phase 3 27, Phase 2/3 5, Phase 2 100, Phase 1/2 59, Phase 1 101) 2018: 342 trials (Observational 34, Not applicable 23, Phase 4 3, Phase 3 14, Phase 2 108, Phase 1/2 48, Phase 1 112) 2019: 360 trials (Observational 44, Not applicable 35, Phase 4 10, Phase 3 18, Phase 2/3 3, Phase 2 90, Phase 1/2 40, Phase 1 120) 2020: 372 trials (Observational 61, Not applicable 30, Phase 4 2, Phase 3 13, Phase 2/3 3, Phase 2 105, Phase 1/2 48, Phase 1 110) 2021: 431 trials (Observational 63, Not applicable 55, Phase 4 7, Phase 3 26, Phase 2/3 2, Phase 2 111, Phase 1/2 56, Phase 1 111) 2022: 439 trials (Observational 64, Not applicable 73, Phase 4 8, Phase 3 25, Phase 2/3 4, Phase 2 96, Phase 1/2 56, Phase 1 113) 2023: 416 trials (Observational 73, Not applicable 66, Phase 4 6, Phase 3 21, Phase 2/3 2, Phase 2 92, Phase 1/2 56, Phase 1 100) 2024: 427 trials (Observational 69, Not applicable 67, Phase 4 5, Phase 3 19, Phase 2/3 6, Phase 2 129, Phase 1/2 42, Phase 1 90) 2025: 426 trials (Observational 78, Not applicable 55, Phase 4 8, Phase 3 19, Phase 2/3 9, Phase 2 122, Phase 1/2 50, Phase 1 85)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 363
2025 426
2024 427
2023 416
2022 439
2021 431
2020 372
2019 360
2018 342
2017 379

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 430 trials starting in 2026 and about 430 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 1,083 trials still running at the 2026-10-09 snapshot; registered median of 41 months across 4,894 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Lymphoma trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 2,032
Phase 1/2 969
Phase 2 2,632
Phase 2/3 76
Phase 3 617
Phase 4 145
Not applicable 801
Observational 1,037
Expanded access 33
Unknown 1

How many Lymphoma trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 320
Recruiting 1,154
Enrolling by invitation 34
Active, not recruiting 612
Available 11

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Lymphoma trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 411
Hoffmann-La Roche 89
Novartis Pharmaceuticals 76
Celgene 66
Children's Oncology Group 57

Which drugs are being tested for Lymphoma? (4)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
RITUXIMAB 1,005
Cytoxan 891
Prednisone 375
Melphalan 176

Interventions as named in the registry (11)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Doxorubicine 436
SQ Fludarabine 431
Vincristina 427
Etoposid 382
Cytarabine IT 257

Showing 5 of 11 interventions.

Start your 14-day trial Email me all 11 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Lymphoma trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Febrile neutropenia 4,084 495
Pneumonia 3,277 465
Neutrophil count decreased 2,335 193
Pyrexia 2,204 365
Sepsis 1,843 472

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Lymphoma? (762)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
TQB3617, a bromodomain and extra-terminal inhibitor, in patients with relapsed or refractory lymphoma: A multicenter, phase 1 trial. Med (New York, N.Y.) 2026 Yes
A first-line regimen combining Bruton's tyrosine kinase and programmed cell death protein-1 inhibitors with chemotherapy excluding methotrexate achieves high response rates in primary central nervous system lymphoma. Cancer 2026 Yes
Differential antibody response to EBV proteome following EBVST immunotherapy in EBV-associated lymphomas. Blood advances 2025 Yes
Phase 1 studies of the indenoisoquinolines LMP776 and LMP744 in patients with solid tumors and lymphomas. Cancer chemotherapy and pharmacology 2025 Yes
Phase I and II Clinical Studies of the STING Agonist Ulevostinag with and without Pembrolizumab in Participants with Advanced or Metastatic Solid Tumors or Lymphomas. Clinical cancer research : an official journal of the American Association for Cancer Research 2025 Yes

Showing 5 of 762 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Lymphoma 223735 Exact Orphadata Science knowledge files, Product 1
Lymphoma 223735 Exact Orphanet Rare Disease Ontology (ORDO)

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence.

Browse all condition evidence pages